Zimmer Biomet (ZBH) Tuesday said it received CE Mark approval for its RibFix Advantage intrathoracic fixation system, allowing sales in the European Economic Area and other markets recognizing the designation.
The system is designed to stabilize and fuse rib fractures using a minimally invasive approach compared to traditional surgical techniques. It adapts to the rib's anatomy during tightening to help reduce the fracture, according to the company.
Zimmer Biomet said this is the first CE Mark approval for an intrathoracic rib fixation system.
Price: 112.32, Change: -0.86, Percent Change: -0.76
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。